SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 110.75 |
| Enterprise Value ($M) | 98.25 |
| Book Value ($M) | 91.73 |
| Book Value / Share | 2.29 |
| Price / Book | 1.21 |
| NCAV ($M) | 85.66 |
| NCAV / Share | 2.13 |
| Price / NCAV | 1.29 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.60 |
| Return on Assets (ROA) | -0.42 |
| Return on Equity (ROE) | -0.45 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 12.00 |
| Current Ratio | 12.00 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 96.08 |
| Assets | 102.15 |
| Liabilities | 10.42 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Nantahala Capital Management, LLC | 9.90 | ||
| 13G/A | Vivo Opportunity Fund Holdings, L.P. | 8.20 | 0.00 | |
| 13G/A | Stonepine Capital Management, LLC | 7.00 | -8.37 | |
| 13G/A | First Manhattan Co | 6.77 | -14.16 | |
| 13G/A | Federated Hermes, Inc. | 19.99 | 9.27 | |
| 13D/A | Genexine Inc. | 4.96 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 25,031 | 124,712 | 20.07 | |
| 15,363 | 105,216 | 14.60 | |
| 18,752 | 188,637 | 9.94 | |
| 10,081 | 28,405 | 35.49 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| RNAZ – TransCode Therapeutics, Inc. | RNXT – RenovoRx, Inc. |
| RVPH – Reviva Pharmaceuticals Holdings, Inc. | SABS – SAB Biotherapeutics, Inc. |
| SAVA – Cassava Sciences, Inc. |
Financial data and stock pages provided by
Fintel.io